Tokyo, Oct. 31 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000063475) titled 'Observational study of zongertinib in patients with HER2-mutated NSCLC in Japan (J-HERZ)' on Oct. 30.
Study Type:
Observational
Primary Sponsor:
Institute - Nippon Boehringer Ingelheim Co., Ltd.
Condition:
Condition - HER2-mutated NSCLC
Classification by malignancy - Malignancy
Genomic information - YES
Objective:
Narrative objectives1 - To assess the rwORR of zongertinib as 1L treatment in Japanese patients with HER2-mutated NSCLC,including subgroup analyses by HER2 mutation subtype(TKD and non-TKD mutations).
Basic objectives2 - Efficacy
Eligibility:
Age-lower limit - 18
years-old
= 18 years
(2)Patients with m...